Condition: Waldenstrom Macroglobulinemia · Sponsor: BeiGene
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
This description comes directly from the study's public registry record.
Study Director · 1-877-828-5568 · clinicaltrials@beigene.com
Always discuss trial participation with your own doctor first.
| Clearview Cancer Institute | Huntsville, Alabama, United States | Recruiting |
| South Alabama Medical Science Foundation Mitchell Cancer Institute | Mobile, Alabama, United States | Recruiting |
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| Los Angeles Cancer Network (Lacn) | Glendale, California, United States | Recruiting |
| Eisenhower Medical Center, Lucy Curci Cancer Center | Rancho Mirage, California, United States | Recruiting |
| Hattiesburg Hematology and Oncology Clinic | Hattiesburg, Mississippi, United States | Recruiting |
| Comprehensive Cancer Centers of Nevada | Las Vegas, Nevada, United States | Recruiting |
| Pan American Oncology Trials, Llc | Rio Piedras, Puerto Rico | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05640102